Literature DB >> 19934400

Genetic predictors of interindividual variability in hepatic CYP3A4 expression.

Vishal Lamba1, John C Panetta, Stephen Strom, Erin G Schuetz.   

Abstract

Variability in hepatic CYP3A4 cannot be explained by common CYP3A4 coding variants. We previously identified polymorphisms in pregnane X receptor (PXR) and ATP-binding cassette subfamily B member 1 (ABCB1) associated with CYP3A4 mRNA levels in small cohorts of human livers. However, the relative contributions of these genetic variations or of polymorphisms in other CYP3A4 regulators to variable CYP3A4 expression were not known. We phenotyped livers from white donors (n = 128) by quantitative real-time polymerase chain reaction for expression of CYP3A4, CYP3A5, and CYP3A7 and nine transcriptional regulators, coactivators, and corepressors. We resequenced hepatic nuclear factor-3-beta (HNF3beta, FoxA2), HNF4alpha, HNF3gamma (FoxA3), nuclear receptor corepressor 2 (NCoR2), and regions of the CYP3A4 promoter and genotyped informative single-nucleotide polymorphisms in PXR and ABCB1 in the same livers. CYP3A4 mRNA was positively correlated with PXR and FoxA2 and negatively correlated with NCoR2 mRNA. A common silent polymorphism and a polymorphic trinucleotide (CCT) repeat in FoxA2 were associated with CYP3A4 expression. The transcriptional activity of the FoxA2 polymorphic CCT repeat alleles (wild-type, n = 14 and variant, n = 13, 15, and 19) when assayed by luciferase reporter transactivation assays was greatest for the wild-type repeat, with deviations from this number having decreased transcriptional activity. This corresponded with higher expression of FoxA2 mRNA and its targets PXR and CYP3A4 in human livers with (CCT) n = 14 genotypes. Multiple linear regression analysis was used to quantify the contributions of selected genetic polymorphisms to variable CYP3A4 expression. This approach identified sex and polymorphisms in FoxA2, HNF4alpha, FoxA3, PXR, ABCB1, and the CYP3A4 promoter that together explained as much as 24.6% of the variation in hepatic CYP3A4 expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19934400      PMCID: PMC2835441          DOI: 10.1124/jpet.109.160804

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  41 in total

1.  The metabolism of drugs by liver microsomes from alloxan-diabetic rats.

Authors:  R L DIXON; L G HART; J R FOUTS
Journal:  J Pharmacol Exp Ther       Date:  1961-07       Impact factor: 4.030

2.  Association of cytosine-adenine repeat polymorphism of the estrogen receptor-beta gene with menopausal symptoms.

Authors:  Chikari Takeo; Etsuko Negishi; Aya Nakajima; Koichi Ueno; Ichiro Tatsuno; Yasushi Saito; Keiko Amano; Aizan Hirai
Journal:  Gend Med       Date:  2005-06

3.  Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes.

Authors:  Christian Wolfrum; Esra Asilmaz; Edlira Luca; Jeffrey M Friedman; Markus Stoffel
Journal:  Nature       Date:  2004-12-23       Impact factor: 49.962

Review 4.  The Foxa family of transcription factors in development and metabolism.

Authors:  J R Friedman; K H Kaestner
Journal:  Cell Mol Life Sci       Date:  2006-10       Impact factor: 9.261

5.  Plasticity and expanding complexity of the hepatic transcription factor network during liver development.

Authors:  Irene Kyrmizi; Pantelis Hatzis; Nitsa Katrakili; Francois Tronche; Frank J Gonzalez; Iannis Talianidis
Journal:  Genes Dev       Date:  2006-08-15       Impact factor: 11.361

Review 6.  Transcriptional regulation and expression of CYP3A4 in hepatocytes.

Authors:  Celia P Martínez-Jiménez; Ramiro Jover; M Teresa Donato; José V Castell; M José Gómez-Lechón
Journal:  Curr Drug Metab       Date:  2007-02       Impact factor: 3.731

7.  The initiation of liver development is dependent on Foxa transcription factors.

Authors:  Catherine S Lee; Joshua R Friedman; James T Fulmer; Klaus H Kaestner
Journal:  Nature       Date:  2005-06-16       Impact factor: 49.962

8.  A "silent" polymorphism in the MDR1 gene changes substrate specificity.

Authors:  Chava Kimchi-Sarfaty; Jung Mi Oh; In-Wha Kim; Zuben E Sauna; Anna Maria Calcagno; Suresh V Ambudkar; Michael M Gottesman
Journal:  Science       Date:  2006-12-21       Impact factor: 47.728

9.  Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver.

Authors:  Kouichi Nakamura; Rick Moore; Masahiko Negishi; Tatsuya Sueyoshi
Journal:  J Biol Chem       Date:  2007-01-30       Impact factor: 5.157

10.  MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype.

Authors:  Jatinder Lamba; Stephen Strom; Raman Venkataramanan; Kenneth E Thummel; Yvonne S Lin; Wei Liu; Cheng Cheng; Vishal Lamba; Paul B Watkins; Erin Schuetz
Journal:  Clin Pharmacol Ther       Date:  2006-02-20       Impact factor: 6.875

View more
  38 in total

Review 1.  CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents.

Authors:  Cody J Peer; Tristan M Sissung; William D Figg
Journal:  Cancer Biol Ther       Date:  2011-03-15       Impact factor: 4.742

2.  Gender differences in pharmacokinetics of maintenance dosed buprenorphine.

Authors:  David E Moody; Wenfang B Fang; Jerdravee Morrison; Elinore McCance-Katz
Journal:  Drug Alcohol Depend       Date:  2011-04-23       Impact factor: 4.492

Review 3.  Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.

Authors:  Timothy S Tracy; Amarjit S Chaudhry; Bhagwat Prasad; Kenneth E Thummel; Erin G Schuetz; Xiao-Bo Zhong; Yun-Chen Tien; Hyunyoung Jeong; Xian Pan; Laura M Shireman; Jessica Tay-Sontheimer; Yvonne S Lin
Journal:  Drug Metab Dispos       Date:  2015-12-17       Impact factor: 3.922

Review 4.  Role of xenobiotic metabolism in cancer: involvement of transcriptional and miRNA regulation of P450s.

Authors:  Viola Tamási; Katalin Monostory; Russell A Prough; András Falus
Journal:  Cell Mol Life Sci       Date:  2010-12-24       Impact factor: 9.261

5.  Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.

Authors:  Rohitash Jamwal; Suzanne M de la Monte; Ken Ogasawara; Sravani Adusumalli; Benjamin B Barlock; Fatemeh Akhlaghi
Journal:  Mol Pharm       Date:  2018-06-11       Impact factor: 4.939

6.  Functional characterization of a full length pregnane X receptor, expression in vivo, and identification of PXR alleles, in zebrafish (Danio rerio).

Authors:  Afonso C D Bainy; Akira Kubota; Jared V Goldstone; Roger Lille-Langøy; Sibel I Karchner; Malin C Celander; Mark E Hahn; Anders Goksøyr; John J Stegeman
Journal:  Aquat Toxicol       Date:  2013-09-20       Impact factor: 4.964

7.  Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients.

Authors:  Dirk Jan A R Moes; Rogier R Press; Jan den Hartigh; Tahar van der Straaten; Johan W de Fijter; Henk-Jan Guchelaar
Journal:  Clin Pharmacokinet       Date:  2012-07-01       Impact factor: 6.447

8.  Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.

Authors:  Muriel Noetzli; Monia Guidi; Karsten Ebbing; Stephan Eyer; Laurence Wilhelm; Agnès Michon; Valérie Thomazic; Ioana Stancu; Abdel-Messieh Alnawaqil; Christophe Bula; Serge Zumbach; Michel Gaillard; Panteleimon Giannakopoulos; Armin von Gunten; Chantal Csajka; Chin B Eap
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

9.  Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.

Authors:  Yogita Ghodke Puranik; Angela K Birnbaum; Susan E Marino; Ghada Ahmed; James C Cloyd; Rory P Remmel; Ilo E Leppik; Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2013-01       Impact factor: 2.533

10.  Bioactivation of Trimethoprim to Protein-Reactive Metabolites in Human Liver Microsomes.

Authors:  Jennifer L Goldman; Yakov M Koen; Steven A Rogers; Kelin Li; James S Leeder; Robert P Hanzlik
Journal:  Drug Metab Dispos       Date:  2016-07-25       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.